Future hepatitis C virus treatment: interferon-sparing combinations.

Area of Science:

• Hepatology and Viral Gastroenterology
• Infectious Diseases and Virology
• Pharmacology and Drug Development

Background:

• Chronic hepatitis C virus (HCV) infection impacts millions globally, with significant projected increases in cirrhosis and end-stage liver disease by 2030.
• Current standard-of-care, pegylated interferon plus ribavirin, exhibits limited efficacy and tolerability issues, leading many patients to be unsuitable or decline treatment.
• Significant side-effects of current therapy, including for patients with decompensated cirrhosis or severe psychiatric illness, highlight an unmet medical need.

Purpose of the Study:

• To evaluate the potential of direct-acting antiviral agents (DAAs) to address the limitations of current hepatitis C virus (HCV) treatments.
• To explore interferon-free treatment regimens combining multiple DAAs targeting different stages of HCV replication.
• To determine optimal DAA combinations, number of agents, and therapy durations for maximizing cure rates while minimizing multi-resistance.

Main Methods:

• Review of current treatment guidelines and emerging direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection.
• Analysis of clinical trial data on protease inhibitors, non-nucleoside polymerase inhibitors, nucleoside polymerase inhibitors, NS5A inhibitors, and cyclophyllin B inhibitors.
• Assessment of strategies for developing interferon-free regimens and managing potential drug resistance.

Main Results:

• Addition of protease inhibitors to standard therapy increases efficacy and shortens treatment for HCV GT1, potentially becoming a new standard of care.
• Triple therapy with protease inhibitors is not suitable for non-1 HCV genotypes or patients with interferon contraindications.
• Combination of multiple DAAs targeting different HCV replication steps is being investigated for interferon-free treatment regimens.

Conclusions:

• Direct-acting antiviral agents (DAAs) represent a promising approach to overcome the limitations of current hepatitis C virus (HCV) therapies.
• Interferon-free regimens combining multiple DAAs are anticipated to offer improved efficacy and tolerability, broadening treatment access.
• Ongoing and planned studies are crucial for optimizing DAA combinations and treatment durations to achieve high cure rates and prevent resistance.